- Home
- TRNR vs PPBT Comparison
TRNR vs PPBT Comparison
Compare TRNR & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRNR | PPBT |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8M | 2.4M |
| IPO Year | 2023 | 2014 |
Fundamental Metrics
Financial Performance| Metric | TRNR | PPBT |
|---|---|---|
| Price | $1.22 | $1.28 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 25.8K | ★ 26.3K |
| Earning Date | 11-16-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,530,000.00 | N/A |
| Revenue This Year | $117.64 | N/A |
| Revenue Next Year | $10.59 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 114.31 | N/A |
| 52 Week Low | $1.11 | $0.41 |
| 52 Week High | $3,281.60 | $5.18 |
Technical Indicators
Market Signals| Indicator | TRNR | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | 24.19 | 61.55 |
| Support Level | N/A | $1.39 |
| Resistance Level | $3.23 | $1.60 |
| Average True Range (ATR) | 0.16 | 0.11 |
| MACD | 0.09 | 0.05 |
| Stochastic Oscillator | 20.85 | 98.11 |
Price Performance
Historical ComparisonAbout TRNR Interactive Strength Inc.
Interactive Strength Inc provides an integrated home fitness platform that allows its customers to participate in interactive wellness and strength-based training sessions. Its health coaching services encompass guidance and coaching on nutrition, recovery, sleep, and other health and lifestyle categories. The company generates revenue from sales of its connected fitness products, membership revenue, and personal training revenue.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.